Related Experiment Video
Updated: Oct 4, 2026
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
Published on: September 5, 2018
Use of isogenic human cancer cells for high-throughput screening and drug discovery
C J Torrance1, V Agrawal, B Vogelstein
1The Howard Hughes Medical Institute, 1650 Orleans Street, Baltimore, MD 21231, USA.
Abstract:
Cell-based screening for novel tumor-specific drugs has been compromised by the lack of appropriate control cells. We describe a strategy for drug screening based on isogenic human cancer cell lines in which key tumorigenic genes have been deleted by targeted homologous recombination. As a test case, a yellow fluorescent protein (YFP) expression vector was introduced into the colon cancer cell line DLD-1, and a blue fluorescent protein (BFP) expression vector was introduced into an isogenic derivative in which the mutant K-Ras allele had been deleted. Co-culture of both cell lines allowed facile screening for compounds with selective toxicity toward the mutant Ras genotype. Among 30,000 compounds screened, a novel cytidine nucleoside analog was identified that displayed selective activity in vitro and inhibited tumor xenografts containing mutant Ras. The present data demonstrate a broadly applicable approach for mining therapeutic agents targeted to the specific genetic alterations responsible for cancer development.
Insights
Researchers developed a new method for finding cancer drugs using genetically matched cells. This approach identified a novel compound effective against tumors with specific gene mutations, offering a promising strategy for targeted cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Developing targeted cancer drugs requires precise control cells for screening.
- Existing methods are limited by the lack of suitable isogenic cell lines.
- Key tumorigenic genes often drive cancer development.
Purpose of the Study:
- To establish a novel cell-based screening strategy for identifying tumor-specific drugs.
- To demonstrate the utility of isogenic cell lines for drug discovery.
- To identify novel therapeutic agents targeting specific genetic alterations in cancer.
Main Methods:
- Utilized targeted homologous recombination to create isogenic human cancer cell lines with deleted key tumorigenic genes.
- Engineered DLD-1 colon cancer cells and an isogenic derivative (K-Ras deleted) with distinct fluorescent protein markers (YFP and BFP).
- Co-cultured engineered cell lines for high-throughput screening of 30,000 compounds.
Main Results:
- Identified a novel cytidine nucleoside analog with selective toxicity against mutant Ras genotype.
- Demonstrated in vitro efficacy and in vivo inhibition of tumor xenografts harboring mutant Ras.
- Validated the screening approach for discovering targeted therapeutic agents.
Conclusions:
- Isogenic cell line co-culture provides a broadly applicable platform for mining cancer drug candidates.
- The identified cytidine nucleoside analog shows potential as a targeted therapy for Ras-driven cancers.
- This strategy enables the development of drugs tailored to specific cancer-driving genetic alterations.
Related Concept Videos
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...